logo
Share SHARE
FONT-SIZE Plus   Neg

Amylin Pharma, Lilly Say BYETTA Approved For Use With Basal Insulin In Europe

Amylin Pharmaceuticals, Inc. (AMLN: Quote) and Eli Lilly and Co. (LLY: Quote) said the European Commission has granted marketing authorization to BYETTA as an adjunctive therapy to basal insulin, with or without metformin and/or Actos, for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The company noted that patients in the pivotal study achieved better glycemic control overall and after meals.

"The marketing authorization for the use of BYETTA with basal insulin provides a new option for the many patients with type 2 diabetes who are not achieving treatment goals," said Christian Weyer, senior vice president, research and development, Amylin Pharmaceuticals. "In a clinical trial, patients using fixed-dose BYETTA with titrated basal insulin achieved better postprandial and overall glycemic control, without weight gain or an increased risk of hypoglycemia, compared to patients using titrated basal insulin without BYETTA."

The main study included in the EU marketing authorization submission package was a double-blind, 30-week clinical trial published in Annals of Internal Medicine.

Further, as part of the transition plan outside the U.S., Amylin will assume responsibility for exenatide product commercialization efforts on a market-by-market basis by the end of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber Technologies Inc., the company behind the famous ride-sharing app, is expanding its pilot food delivery service program, UberEATS, to New York City and Chicago. Uber's new pilot program allows customers to order a meal that will be delivered to them within ten minutes. There is a $3 delivery... Standard Chartered said it is still reviewing whether to shift its headquarters out of London, at a time when banks in Britain face higher levy and regulatory costs. Tyson Foods Inc. (TSN) Tuesday said it plans to eliminate the use of human antibiotics from its chicken production, as the meat producing giant joins other peers who have taken similar steps in the wake of health concerns. Tyson Foods said it is striving to eliminate the use of antibiotics from its...
comments powered by Disqus
RELATED NEWS
Trade LLY now with 
Follow RTT